ATE277616T1 - Synergistische kombination von roflumilast und pde-3 hemmern - Google Patents

Synergistische kombination von roflumilast und pde-3 hemmern

Info

Publication number
ATE277616T1
ATE277616T1 AT00927094T AT00927094T ATE277616T1 AT E277616 T1 ATE277616 T1 AT E277616T1 AT 00927094 T AT00927094 T AT 00927094T AT 00927094 T AT00927094 T AT 00927094T AT E277616 T1 ATE277616 T1 AT E277616T1
Authority
AT
Austria
Prior art keywords
pde
sub
roflumilast
inhibitors
synergistic combination
Prior art date
Application number
AT00927094T
Other languages
English (en)
Inventor
Hermann Amschler
Rolf Beume
Dietrich Haefner
Christian Schudt
Armin Hatzelmann
Ulrich Kilian
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE277616T1 publication Critical patent/ATE277616T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00927094T 1999-05-04 2000-04-27 Synergistische kombination von roflumilast und pde-3 hemmern ATE277616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108808 1999-05-04
PCT/EP2000/003838 WO2000066123A1 (en) 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor

Publications (1)

Publication Number Publication Date
ATE277616T1 true ATE277616T1 (de) 2004-10-15

Family

ID=8238107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927094T ATE277616T1 (de) 1999-05-04 2000-04-27 Synergistische kombination von roflumilast und pde-3 hemmern

Country Status (11)

Country Link
US (2) US6498173B1 (de)
EP (1) EP1176960B1 (de)
JP (1) JP2002543133A (de)
AT (1) ATE277616T1 (de)
AU (1) AU4558800A (de)
CA (1) CA2372850C (de)
DE (1) DE60014353T2 (de)
ES (1) ES2228512T3 (de)
PT (1) PT1176960E (de)
SI (1) SI1176960T1 (de)
WO (1) WO2000066123A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6196201A (en) * 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses

Also Published As

Publication number Publication date
EP1176960A1 (de) 2002-02-06
DE60014353D1 (de) 2004-11-04
SI1176960T1 (en) 2005-04-30
US6498173B1 (en) 2002-12-24
CA2372850C (en) 2011-01-18
US20030050329A1 (en) 2003-03-13
AU4558800A (en) 2000-11-17
US6897229B2 (en) 2005-05-24
PT1176960E (pt) 2005-02-28
ES2228512T3 (es) 2005-04-16
EP1176960B1 (de) 2004-09-29
WO2000066123A1 (en) 2000-11-09
DE60014353T2 (de) 2005-10-13
JP2002543133A (ja) 2002-12-17
CA2372850A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
DK1202986T3 (da) Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
DE60014353D1 (de) Synergistische kombination von roflumilast und pde-3 hemmern
EE200300227A (et) P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
NZ334476A (en) substituted indol-3-yl glyoxylamides
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
AU2483000A (en) Treatment of asthma with mek inhibitors
HUP0000487A2 (hu) Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
NO20014479D0 (no) Fremgangsmåte ved behandling av spiseforstyrrelser
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
AU2003217074A1 (en) N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
MXPA03009750A (es) Compuestos quimicos.
NO20053046L (no) 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SG52662A1 (en) Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ATE236169T1 (de) Heterocyclisch kondensierte morphinoid-derivate
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
ATE279924T1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5- dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
WO2001089498A3 (en) USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1176960

Country of ref document: EP

EEIH Change in the person of patent owner